transvaal apotheek cbd

December 15, 2021 By admin Off

We are glad to announce that within a couple of months the Transvaal Apotheek will work with Target Healthcare to produce the cannabis oil in the UK. As health care providers we feel that it is our duty to continue the supply for this small group of patients who rely on our products. For these patients switching to other cannabis-based products can lead to serious adverse events.

The prescription has to contain the following information:


Specialist in eigen bereidingen en palliatieve zorg.

Monday-Friday: 10:00 – 16:00 Phone: 070-2055637 Contact person: Natalie Chan, pharmacist Mail: [email protected]

Collecting is only possible after we receive the payment. You will receive an automatic email when your order is ready for pick-up. You may come to the pharmacy for pick-up yourself. Due to COVID19, pick-up by courier medicinal cannabis oil is temporarily allowed for Ireland and the UK. You need to arrange your own courier and import license. We only work with Fedex. Please send us the courier label in advance.

You will receive an invoice by mail. Please use the button below for payment after you have received an invoice.

– Last name, initial(s), address and telephone number of the physician – Date of prescribing – Dosage – Name of the variety and quantity – Signature of the physician – Name, gender, date of birth, address and telephone number of the pat i ent.

We are not allowed to post medicinal cannabis via courier for other countries than Ireland and the UK.

In order to provide you the cannabis oil, we need to receive a prescription of a licensed physician. You can mail the prescription to [email protected]


For the UK it is also allowed to use the following companies for pick-up:

UK statement.

Target Health care Miller and Miller Chemicals Rokshaw Laboratories Lyphe group.

For private persons.

Mrs Griffiths said Ben had been using the oils for the past two years and they had given him "the first seizure-free days of his life".

Transvaal Apotheek said it was working with Scottish company Target Healthcare to soon produce the drug in the UK.

He also has brain damage, cerebral palsy and autism.

"We have obviously been very keen to keep Ben and other children out of hospital, so by keeping Ben on the same product we think we've got a very good chance of that."

"The prospect of it being produced in the UK, though, is really good news because it means parents don't need to travel abroad – when they can, anyway – to try and bring it back."

She said she was relieved to hear of the plans to produce the oil in the UK.

"It will be exactly the same product, same method to produce, the same medicine, essentially," she said.

Her supplies were boosted when the UK government struck a temporary deal with Dutch authorities to supply cannabis oil until July.

Ever since he was born, Ben has had up to 300 seizures a day, some lasting for up to an hour.

Mrs Griffiths said: "We're really grateful the government recognised the need for at least the short-term solution.

Joanne Griffiths said 11-year-old Ben's drugs, dispensed in the Netherlands, could no longer be imported.

Mrs Griffiths, 45, from Preston, said it was "amazing news" for her son and other patients.

Sam Mountney, from charity Epilepsy Action, said it was working with the Department of Health and Social Care and affected families on a "long-term solution" to the post-Brexit supply of the oils.

Patients should take into account that inhaling cannabis results in a higher uptake than when using other administration routes. Patients have to dose carefully when changing to a different variety, especially if they have previously used cannabis with a lower content of THC/CBD.

“The only known contra-indications include schizophrenia, arrhythmia and other heart conditions. We work closely with prescribing doctors and also provide adequate instructions to patients about the benefits and risk of their medicines.”

“Pharmacovigilance (see Section 8) is an important role of a pharmacist. We seek feedback from patients on the safety, effectiveness and adverse reactions they experience from their medicine use. We are also required to provide adequate instructions and honest information to patients about the benefits and risk of their medicines.”

What are the key risks of using cannabis as a therapeutic product?

“The biggest risk is getting high and triggering psychoses (especially with psychiatric patients) or worsening current depression. There are risks in prescribing in the elderly, and the potential long-term effects on children are still unknown.”

In a follow-up discussion we ask the patient about their experience with the use of medicinal cannabis, with extra attention to side-effects and effectiveness.”

“First we ask the patient what they already know about medicinal cannabis. Then we inform them about the mechanism of action, how to use it, the dosage regimen, possible side-effects, how to safely store it. Finally we make sure that the patient takes notice of possible interactions with other medicines or contra-indications (certain conditions where medicinal cannabis should not be used).

“We recommend patients inhale 1-2 times a day until the desired effect is achieved or until (psychotropic) side effects occur. This means they have had too much. Per inhalation, we recommend patients wait at least 5 minutes between the inhalations.

“In accordance with their doctor’s prescription, we suggest that patients start low and go slow. As a starting dose for oil, we recommend to use 2 drops (0,05ml) under the tongue, 3 times a day and increase the dose until the desired effect is achieved. The maximum dosage is 10 drops (0,25ml), 3 times a day.

The ‘steady state’ concentration of THC/CBD and the active metabolite is reached after 1-2 weeks. Like oral dosing, this time span should be taken into account for the assessment of the medicines effectiveness for the patient.”

From a pharmacist’s point of view, what are the actual and potential complications with medicinal cannabis?

“We know that cannabis is metabolised by CYP450 enzymes. When taken together with other medicines metabolised by the same enzymes, there may be the potential for drug-drug interactions. We discuss with patients about the risk of using such medicines concurrently, or recommend alternative medications.”

The ‘steady state’ concentration of THC/CBD and the active metabolite is reached after 1-2 weeks. This time span should be taken into account for the assessment of the medicines effectiveness for the patient.”

“Not often. We identify this issue by monitoring the quantities dispensed and the frequency of dispensing. We make an agreement with the patient to avoid further misuse. If this doesn’t help, we consult the prescribing doctor and find solutions to the problem.”

“Get training or read a lot into the subject, because patients are generally quite well informed but also misinformed.”

Do you encounter diversion for misuse or abuse?